title: Tumor cell p38 MAPK: A trigger of cancer bone osteolysis.
abstract: Osteolytic bone destruction is a hallmark of bone-metastatic cancers. Current therapy is unable to completely cure or prevent this disease in patients. The p38 mitogen-activated protein kinase (MAPK) affects a diverse range of intracellular responses with well-known roles in development, cell-cycle and differentiation, inflammation, apoptosis, senescence, and tumorigenesis. This article is an overview of the contribution of tumor cell-expressed p38 MAPK to the regulation of osteoclastogenesis, osteoblastogenesis, and osteolyticbone lesions.
authors.affiliation: Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
authors.forename: Huan
authors.initials: H
authors.lastname: Liu
authors.affiliation: Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
authors.forename: Jin
authors.initials: J
authors.lastname: He
authors.affiliation: Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA ; Cancer Research Institution, Guangzhou Medical University, Guangzhou, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Yang
keywords: bone destruction; breast cancer; cytokines; multiple myeloma; p38 MAPK